Iterum Therapeutics plc
ITRMFDrugs in Pipeline
4
Phase 3 Programs
4
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
Ertapenem
Intra Abdominal Infections
Sulopenem
Complicated Urinary Tract Infections
Sulopenem etzadroxil/probenecid
Urinary Tract Infections
Sulopenem-Etzadroxil/Probenecid
Uncomplicated Urinary Tract Infections
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Ertapenem | Phase 3 | Intra Abdominal Infections | - | - |
Sulopenem | Phase 3 | Complicated Urinary Tract Infections | - | - |
Sulopenem etzadroxil/probenecid | Phase 3 | Urinary Tract Infections | - | - |
Sulopenem-Etzadroxil/Probenecid | Phase 3 | Uncomplicated Urinary Tract Infections | - | - |
Frequently asked questions
What is in Iterum Therapeutics plc's drug pipeline?→
CatalystAlert tracks 4 drug candidates in Iterum Therapeutics plc's (ITRMF) pipeline across Phase 3. Its lead program is Ertapenem (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Iterum Therapeutics plc's next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Iterum Therapeutics plc (ITRMF) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track ITRMF biotech catalysts?→
Add ITRMF to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Iterum Therapeutics plc's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.